



Methyl 3-bromomethyl-3-butenolate as an isopentane building block for the stereoselective preparation of (*S*)-4-methyl-3,6-dihydro-2*H*-pyran-2-carbaldehyde and (+)-faranal

Iryna V. Mineyeva, Oleg G. Kulinkovich*

Department of Organic Chemistry, Belarusian State University, Nezavisimosti Av. 4, Minsk 220030, Belarus

ARTICLE INFO

Article history:

Received 4 December 2009

Revised 19 January 2010

Accepted 29 January 2010

Available online 4 February 2010

Keywords:

Cyclopropanols

Allyl halides

(+)-Faranal

Ring opening

Asymmetric synthesis


ABSTRACT

(*S*)-4-Methyl-3,6-dihydro-2*H*-pyran-2-carbaldehyde (**3**), the common intermediate in the syntheses of the C17–C27 subunit of laulimalide (**4**) and (+)-faranal (**5**), the trail pheromone of the pharaoh ant, *Monomorium pharaonis*, were obtained via transformation of methyl 3-bromomethyl-3-butenolate (**1**) into allylstannane **2** and subsequent allylation of (benzyloxy)acetaldehyde (**6**) in accordance with the Keck procedure as the key steps.

© 2010 Elsevier Ltd. All rights reserved.

3-Methylbut-2-enoic acid and its derivatives are widely used as nucleophilic C₅ building blocks via the generation of a carbanionic centre by allylic deprotonation or metal–halogen exchange reactions.¹ The synthetic application of regioisomeric 3-methylbut-3-enoic acid derivatives has not been studied in detail, and to our knowledge, is limited to asymmetric allylation of aldehydes with ethyl 3-[(tributylstannyl)methyl]but-3-enoate² obtained in turn by ethoxycarbonylation of 1,3-bis-(tributylstannyl)-2-methylenepropane.³ This allylating agent was successfully used for the preparation of δ -hydroxy- β -methylenealkanoic or (*E*)- δ -hydroxy- β -methyl- α,β -alkenoic esters after the displacement of the carbon–carbon double bond to a position conjugated to the carbonyl group.² Recently, we reported an effective preparation of a similar allyl stannane **2** by zinc-mediated stannylation of methyl 3-bromomethyl-3-butenolate (**1**).⁴ Herein, compound **1** was exploited for the stereoselective preparation of (*S*)-4-methyl-3,6-dihydro-2*H*-pyran-2-carbaldehyde (**3**),⁵ a common intermediate in several syntheses of the C17–C27 subunit of laulimalide (**4**),^{5a–i,k,6} as well as in the synthesis of (+)-faranal, [(3*S*,4*R*,6*E*,10*Z*)-3,4,7,11-tetramethyl-6,10-tridecadienal] (**5**), the trail pheromone of the pharaoh ant, *Monomorium pharaonis*⁷ (Scheme 1).


The previously reported syntheses of aldehyde **3** from the appropriate chiral precursors were based mainly on the formation




Scheme 1.

* Corresponding author. Tel.: +375 17 2095459; fax: +375 17 2265609.

E-mail addresses: kulinkovich@bsu.by, o.kulinkovich@gmail.com (O.G. Kulinkovich).



Scheme 2.



Scheme 3.

of a dihydropyran ring by a metathesis reaction.^{5b–k} Its preparation via the enantioselective cycloaddition of α -functionalized aldehydes to isoprene⁸ or 4-methoxyisoprene⁹ in the presence of chiral Cr or Co complexes as catalysts was also reported. In this work,

aldehyde **3** was obtained by transformation of ester **1** into functionalized allyl stannane **2** followed by the addition of the latter to (benzyloxy)acetaldehyde **6**¹⁰ under Keck conditions¹¹ (Scheme 2). When the reaction was carried out in dichloromethane

in the presence of 10 mol % of (*S*)-BITIP catalyst, a complex mixture of products was formed and the conversion of aldehyde **6** was less than 50%. The allylation proceeded sufficiently faster and more smoothly when toluene was used as the solvent.¹¹ In this case, the reaction was accompanied by lactonization of the intermediate homoallylic alcohol and subsequent migration of the carbon–carbon double bond to a position conjugated to the carbonyl group to afford lactone **7**. For the preparation of allyl stannane **2**, allyl bromide **1**, obtained via the cationic cyclopropyl-allyl isomerization of the readily available cyclopropyl sulfonate **8**,^{4,12} was converted on treatment with *p*-TolSO₂Na in *N,N*-dimethylformamide (DMF) into sulfone **9**. The latter was reacted with Bu₃SnH in the presence of AIBN^{13,14} to give **2**. Reduction of lactone **7** with lithium aluminium hydride, followed by treatment of the product diol **10** with zinc dichloride in boiling 1,2-dichloroethane¹⁵ led to dihydropyran **11**.¹⁶ After debenzoylation of **11** with sodium in liquid ammonia, chiral alcohol **12**^{5a–c, g–k, 9a, 17} was obtained in 94% ee.^{18,19} Finally, Swern oxidation gave aldehyde **3** in 23% overall yield based on allyl bromide **1**.

One of the most effective methods for the synthesis of (+)-faranal (**5**), the trail pheromone of the pharaoh ant, a foodstuff pest and a dangerous infection carrier in hospitals,^{7d} was elaborated by Szántay and co-workers.^{7a,b} The authors constructed the carbon skeleton of the molecule via diastereoselective allylation of (3*S*)-methyl valerolactone, which in turn was obtained by enzymatic reduction of methyl glutaconicoate.^{7a,20} We found that lactone **7** could be successfully used to prepare (+)-faranal (**5**) by Szántay's modified procedure (Scheme 3). Diastereoselective reduction of the carbon–carbon double bond in lactone **7** with sodium borohydride in the presence of nickel chloride²¹ followed by deprotection of the hydroxy group of unsaturated lactone **13** led to crystalline *cis*-lactone **14** in 78% yield over two steps.²² The latter was recrystallized twice from a mixture of diethyl ether–ethyl acetate to give the product in greater than 99% ee.^{19,23}

Silylation of the hydroxy group of **14** and subsequent treatment of a mixture of compound **15** and (*Z*)-homogeranyl bromide (**16**)^{7a,b,24} with LDA in tetrahydrofuran initially for 2 h at –78 °C and then for 12 h at –30 °C^{7a,7b,25} led to allylation product **17** which was isolated as a single diastereomer in 60% yield.²⁶ It is noteworthy that the TBS-protecting group in lactone **15** had an important influence on the alkylation process since lactone **13**, unlike **15**, under the same conditions, yielded a complex mixture of products. Reduction of alkylated lactone **17** with lithium aluminium hydride, followed by transformation of the product formed into acetonide derivative **18** and subsequent reductive elimination of the hydroxy group of the latter gave **19**. Hydrolysis of compound **19** and oxidative fragmentation of the formed vicinal diol with phenyliodine(III) diacetate in methanol led to (+)-faranal (**5**) in 28% yield based on lactone **15**.

In summary, methyl 3-bromomethyl-3-butenolate (**1**) was successfully used as a bifunctional isopentane building block in the synthesis of (*S*)-4-methyl-3,6-dihydro-2*H*-pyran-2-carbaldehyde (**3**) and (+)-faranal **5**. The Keck asymmetric condensation of (benzyloxy)acetaldehyde **6** and allyl stannane **2**, derived from allyl bromide **1** was the key step in both syntheses.

References and notes

- (a) Julia, M.; Arnold, D. *Bull. Soc. Chim. Fr.* **1973**, 746; (b) Gedye, R. N.; Arora, P.; Khalil, A. H. *Can. J. Chem.* **1975**, 53, 1943; (c) Cardillo, G.; Orena, M.; Sandri, S. *Tetrahedron* **1976**, 32, 107; (d) Huisman, H. O. *Pure Appl. Chem.* **1977**, 49, 1307; (e) Dugger, R. W.; Heathcock, C. H. *J. Org. Chem.* **1980**, 45, 1181; (f) Cainelli, G.; Cardillo, G. *Acc. Chem. Res.* **1981**, 14, 89; (g) Wang, Y.; Woo, W. S.; Hoef, I.; Lugtenburg, J. *Eur. J. Org. Chem.* **2004**, 2166; (h) Jeon, H.-S.; Yeo, J. E.; Jeong, Y. C. *Synthesis* **2004**, 2813; (i) Salman, M.; Babu, S. J.; Kaul, V. K.; Ray, P. R.; Kumar, N. *Org. Proc. Res. Dev.* **2005**, 9, 302.
- (a) Keck, G. E.; Yu, T. *Org. Lett.* **1999**, 1, 289; (b) Sanchez, C. C.; Keck, G. E. *Org. Lett.* **2005**, 7, 3053.

- Keck, G. E.; Palani, A. *Tetrahedron Lett.* **1993**, 34, 3223.
- Mineyeva, I. V.; Kulinkovich, O. G. *Zh. Org. Khim.* **2008**, 44, 1277; *Russ. J. Org. Chem. (Engl. Trans.)* **2008**, 44, 1261.
- (a) Ghosh, A. K.; Wang, Y. *Tetrahedron Lett.* **2000**, 41, 2319; (b) Ghosh, A. K.; Wang, Y.; Kim, T. K. *J. Org. Chem.* **2001**, 66, 8973; (c) Dorling, E. K.; Öhler, E.; Mulzer, J. *Tetrahedron Lett.* **2000**, 41, 6323; (d) Ahmed, A.; Öhler, E.; Mulzer, J. *Synthesis* **2001**, 2007; (e) Mulzer, J.; Öhler, E. *Angew. Chem., Int. Ed.* **2001**, 40, 3842; (f) Mulzer, J.; Öhler, E. *Angew. Chem.* **2001**, 113, 3961; (g) Mulzer, J.; Öhler, E.; Enev, V. S.; Hanbauer, M. *Adv. Synth. Catal.* **2002**, 344, 3026; (h) Ahmed, A.; Hoegenauer, K.; Enev, V. S.; Hanbauer, M.; Kaehling, H.; Öhler, E.; Mulzer, J. *J. Org. Chem.* **2003**, 68, 3026; (i) Messenger, B. T.; Davidson, B. S. *Tetrahedron Lett.* **2001**, 42, 801; (j) Lee, H. W.; Yoon, S. H.; Lee, I.-Y. C.; Chung, B. Y. *Bull. Korean Chem. Soc.* **2001**, 22, 1179; (k) Sivaramakrishnan, A.; Nadolski, G. T.; McAlexander, I. A.; Davidson, B. S. *Tetrahedron Lett.* **2002**, 43, 213.
- (a) Gollner, A.; Mulzer, J. *Org. Lett.* **2008**, 10, 4701; (b) Gollner, A.; Altmann, K.-H.; Gertsch, J.; Mulzer, J. *Tetrahedron Lett.* **2009**, 50, 5790.
- (a) Poppe, L.; Novák, L.; Kolonits, P.; Bata, A.; Szántay, C. *Tetrahedron Lett.* **1986**, 27, 5769; (b) Poppe, L.; Novák, L.; Kolonits, P.; Bata, A.; Szántay, C. *Tetrahedron* **1988**, 44, 1477; (c) Kobayashi, M.; Koyama, T.; Ogura, K.; Ritter, F. J.; Brüggemann-Rotgans, I. E. M. *J. Am. Chem. Soc.* **1980**, 102, 6602; (d) Knight, D. W.; Ojha, B. A. *J. Chem. Soc., Perkin Trans. 1* **1983**, 955; (e) Baker, R.; Billington, D. C.; Ekanayake, N. *J. Chem. Soc., Perkin Trans. 1* **1983**, 1387; (f) Mori, K.; Ueda, H. *Tetrahedron* **1982**, 38, 1227; (g) Mori, K.; Murata, N. *Liebigs Ann* **1995**, 2089; (h) Vasil'ev, A. A.; Engman, L.; Serebryakov, E. P. *J. Chem. Soc., Perkin Trans. 1* **2000**, 2211.
- (a) Wender, P. A.; Hilinski, M. K.; Soldermann, N.; Mooberry, S. L. *Org. Lett.* **2006**, 8, 1507; (b) Wender, P. A.; Hegde, S. G.; Hubbard, R. D.; Zhang, L. *J. Am. Chem. Soc.* **2002**, 124, 4956.
- (a) Paterson, I.; De Savi, C.; Tudge, M. *Org. Lett.* **2001**, 3, 3149; (b) Paterson, I.; Bergmann, H.; Menche, D.; Berkessel, A. *Org. Lett.* **2004**, 6, 1293.
- Fatima, A.; Pilli, R. A. *Arkivoc* **2003**, x, 118.
- Kurosu, M.; Lorca, M. *Synlett* **2005**, 1109.
- Limbach, M.; Dalai, S.; de Meijere, A. *Adv. Synth. Catal.* **2004**, 346, 760.
- Ueno, Y.; Aoki, S.; Okawara, M. *J. Chem. Soc., Chem. Commun.* **1980**, 683.
- In comparison with the earlier reported one-step procedure,⁴ the advantage of the described method in this two-step approach to the preparation of functionalized allyl stannane **2** from allyl bromide **1** via sulfone **9** is that equimolar quantities of the reagents are used and purification of the product by column chromatography is easier.
- Kim, S.; Chung, K. N.; Yang, S. *J. Org. Chem.* **1987**, 52, 3917.
- Experimental procedure*: A solution of 1.08 g (5 mmol) of diol **10** and 0.8 g (6 mmol) of anhyd ZnCl₂ in 30 ml of dichloroethane was refluxed for 1.5 h. After treatment with H₂O (30 ml) and extraction with CH₂Cl₂ (3 × 25 ml), the combined organic phase was washed with aq NaHCO₃ (40 ml) and dried over anhyd MgSO₄. Following evaporation of the solvent, the residue was purified by column chromatography on silica gel (eluent–petroleum ether/EtOAc), yielding 0.76 g (76%) of **11** as a colourless oil. $[\alpha]_D^{20}$ –75.7 (c 7.1, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.69 (s, 3H), 1.76–1.80 (m, 1H), 2.00–2.07 (m, 1H), 3.47 (dd, *J* = 10.2, 3.8 Hz, 1H), 3.54 (dd, *J* = 10.2, 6.5 Hz, 1H), 3.73–3.79 (m, 1H), 4.17–4.21 (m, 2H), 4.57 (d, *J* = 12.3 Hz, 1H), 4.64 (d, *J* = 12.3 Hz, 1H), 5.42 (br s, 1H), 7.28–7.37 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 23.0, 32.1, 65.8, 72.9, 73.0, 73.5, 119.8, 127.6, 127.8 (2 × C), 128.3 (2 × C), 131.2, 138.2; IR (CCl₄) 1138, 1099 cm^{–1}; Anal. Calcd for C₁₄H₁₈O₂: C, 77.03; H, 8.31. Found: C, 77.10; H, 8.28.
- Lee, H. W.; Yeong, C.-S.; Yoon, S. H.; Choi Lee, I.-Y. *Bull. Korean Chem. Soc.* **2001**, 22, 791.
- The ee value of alcohol **12** was determined by Mosher's method.¹⁹ The signals of the protons of the methoxy groups at δ 3.57 and δ 3.41 were used to determine the enantiomeric purity. Major isomer of (*R*)-(+)-MTPA ester: ¹H NMR (400 MHz, CDCl₃) δ 1.68 (s, 3H), 1.75–1.80 (m, 1H), 1.95–2.05 (m, 1H), 3.57 (s, 3H), 3.75–3.85 (m, 1H), 4.09 (d, *J* = 16.0 Hz, 1H), 4.17 (d, *J* = 16.0 Hz, 1H), 4.37 (dd, *J* = 11.2, 6.0 Hz, 1H), 4.41 (dd, *J* = 11.2, 4.2 Hz, 1H), 5.41 (br s, 1H), 7.35–7.40 (m, 3H), 7.55–7.60 (m, 2H).
- Dale, J. A.; Dull, D. L.; Mosher, H. S. *J. Org. Chem.* **1969**, 34, 2543.
- Horgan, D. J.; Stoops, J. K.; Webb, E. C.; Zerner, B. *Biochemistry* **1969**, 8, 2000.
- (a) Toshio, T.; Kenryo, N.; Shuichi, S. *Chem. Pharm. Bull.* **1971**, 19, 817; (b) Bekish, A. V.; Prokhorevich, K. N.; Kulinkovich, O. G. *Eur. J. Org. Chem.* **2006**, 5069.
- Experimental procedure*: 0.84 g of NaBH₄ (22 mmol) was added in small portions over 10 min each to a stirred emulsion of 2.32 g (10 mmol) of compound **7** in 50 ml THF–H₂O (1:1) at 0 °C, containing 2.60 g (11 mmol) of NiCl₂·6H₂O and 2.34 g (40 mmol) of H₃BO₃. After stirring for an additional 0.5 h, the reaction mixture was extracted with Et₂O (4 × 25 mL). The combined organic fraction was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was chromatographed on silica gel (eluent–petroleum ether/EtOAc) to give **13** (2.20 g, 94%) as a colourless oil. The latter was dissolved in 30 ml of absolute EtOH and stirred under H₂ in the presence of 0.05 g of 10% Pd/C for 2 h. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent–petroleum ether/EtOAc), yielding hydroxymethyl lactone **14** (1.34 g, 99% ee, 86%) as colourless crystals. Crystallization (twice) from Et₂O/EtOAc (10:1) gave 1.12 g (83%) of the product, with ee >99%.²³ Mp 80–81 °C; $[\alpha]_D^{20}$ +11.7 (c 0.6 CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.01 (d, *J* 6.1 Hz, 3H), 1.32–1.42 (m, 1H), 1.58 (br s, 1H), 1.80–1.85 (m, 1H), 1.96–2.07 (m, 2H), 2.58–2.67 (m, 1H), 3.60 (ddd, *J* = 12.3, 6.1, 5.4 Hz, 1H), 3.75 (ddd, *J* = 12.3, 7.4, 2.6 Hz, 1H), 4.34–4.39 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.4, 26.2, 32.2, 37.9, 64.5, 81.1, 171.5; IR (CCl₄) 3439,

- 1732, 1259, 1087 cm^{-1} ; Anal. Calcd for $\text{C}_7\text{H}_{12}\text{O}_3$: C, 58.32; H, 8.39. Found: C, 58.37; H, 8.34.
23. The ee value of **14** was determined by Mosher's method.¹⁹ The signals of the protons of the methoxy groups at δ 3.56 and δ 3.41 were used to determine the enantiomeric purity of **14**. Major isomer of (R)-(+)-MTPA ester: ^1H NMR (400 MHz, CDCl_3) δ 1.02 (d, $J = 6.1$, 3H), 1.23–1.32 (m, 1H), 1.83–1.89 (m, 1H), 1.99–2.10 (m, 2H), 2.66 (ddd, $J = 17.1$, 4.9, 2.1 Hz, 1H), 3.56 (s, 3H), 4.38 (dd, $J = 11.8$, 5.1 Hz, 1H), 4.41 (dd, $J = 11.8$, 3.6 Hz, 1H), 4.52–4.58 (m, 1H), 7.38–7.43 (m, 3H), 7.51–7.57 (m, 2H).
24. (a) Stotter, P. L.; Hornish, R. E. *J. Am. Chem. Soc.* **1973**, 95, 4444; (b) Sen, S. E.; Ewing, G. J. *J. Org. Chem.* **1997**, 62, 3529; (c) Okochi, T.; Mori, K. *Eur. J. Org. Chem.* **2001**, 2145.
25. (a) Posner, G. H.; Loomis, G. L. *Chem. Commun.* **1972**, 892; (b) Herrmann, J. L.; Schlessinger, R. H. *Chem. Commun.* **1973**, 771.
26. **Compound 17**. $[\alpha]_{\text{D}}^{20} -6.1$ (c 0.82, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 0.06 (s, 6H), 0.88 (s, 9H), 0.94 (t, $J = 7.7$ Hz, 3H), 1.05 (d, $J = 6.1$ Hz, 3H), 1.37–1.46 (m, 1H), 1.63 (s, 3H), 1.65 (s, 3H), 1.85–1.93 (m, 2H), 1.97–2.08 (m, 6H), 2.13–2.19 (m, 1H), 2.41 (ddd, $J = 15.1$, 8.4, 4.6 Hz, 1H), 2.69 (dt, $J = 15.1$, 4.9 Hz, 1H), 3.64 (dd, $J = 10.8$, 5.6 Hz, 1H), 3.73 (dd, $J = 10.8$, 4.1 Hz, 1H), 4.21–4.27 (m, 1H), 5.02 (t, $J = 6.4$ Hz, 1H), 5.06 (t, $J = 7.2$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ -5.4 (2 \times C), 12.8, 16.3, 18.3, 20.6, 22.8, 24.7, 26.1 (3 \times C), 27.4, 29.6, 33.9, 40.1, 48.7, 65.3, 79.5, 120.2, 123.7, 137.2, 137.9, 173.3; IR (CCl_4) 1716, 1450, 1268, 1104, 1004 cm^{-1} ; Anal. Calcd for $\text{C}_{24}\text{H}_{44}\text{O}_3\text{Si}$: C, 70.53; H, 10.85. Found: C, 70.59; H, 10.82.